期刊文献+

西格列汀中间体(R)-3-叔丁氧羰基氨基-4-(2,4,5-三氟苯基)丁酸的合成工艺研究

Study on synthetic process of(R)-3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl) butyric acid, an intermediate of sitagliptin
原文传递
导出
摘要 目的优化(R)-3-叔丁氧羰基氨基-4-(2,4,5-三氟苯基)丁酸的合成工艺。方法以2,4,5-三氟苯乙酸为起始原料,经缩合、醇解、氨化"一锅法"得到(Z)-3-氨基-4-(2,4,5-三氟苯基)-2-丁烯酸甲酯,再经氨基乙酰化、不对称氢化、水解、氨基保护制得(R)-3-叔丁氧羰基氨基-4-(2,4,5-三氟苯基)丁酸。结果与结论目标产物的结构经质谱和核磁共振谱确证,总收率53.1%(以2,4,5-三氟苯乙酸计),纯度为99.7%(HPLC法)。该工艺步骤少、操作简单、反应条件温和,可为西格列汀的工业化生产提供有效方法。 (R)-3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl) butyric acid is an important intermediate for the synthesis of sitagliptin.2,4,5-Trifluorophenylacetic acid was used as the raw material, and(Z)-methyl 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoate was obtained by the "one-pot method" of condensation, alcoholysis, and amination.Then(R)-3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butyric acid was prepared via amino acetylation, asymmetric hydrogenation, hydrolysis, and amino protection from(Z)-methyl 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoate.The total yield was 53.1% with the purity of 99.7%(HPLC).The process has fewer steps, simple operation and mild reaction conditions, and provides an effective method for the industrial production of sitagliptin.
作者 高浩凌 查娟 刘建红 盛力 GAO Hao-ling;ZHA Juan;LIU Jian-hong;SHENG Li(Research&Development Center,Zhejiang Medicine Co.,Ltd.,Shaoxing312300,China;Changhai Biological Compamy,Zhejiang Medicine Co.,Ltd.,Shaoxing312300,China;Zhejiang Novus Pharmaceuticals Co.,Ltd.,Shaoxing312300,China)
出处 《中国药物化学杂志》 CAS CSCD 2022年第1期28-31,共4页 Chinese Journal of Medicinal Chemistry
关键词 西格列汀 (R)-3-叔丁氧羰基氨基-4-(2 4 5-三氟苯基)丁酸 不对称氢化 合成工艺 sitagliptin (R)-3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butyric acid asymmetric hydrogenation synthetic process
  • 相关文献

二级参考文献28

  • 1SBOKOVA E, CHRIST A D, BOEHRINGER M, et al. Dipeptidyl peptidase IV inhibitors: the nextgeneration of new promising therapies for the mana- gement of type 2 diabetes E J ]. Curr Top Med Chem, 2007,7(6) :547 -555.
  • 2DRUCKER D,EASLEY C,KIRKPATRICK P. Sitaglip- tin[J]. Nat Rev Drug Discov,2007,6(2) :109 - 110.
  • 3HANSEN K B, BALSELLS J, DREHER S, et al. First generation process for the preparation of the DPP-IV inhibitor sitagliptin [ J ]. Org Pro Res Dev, 2005,9 (5) :634 - 639.
  • 4WU S L, YU B, WANG Y J, et al. Process and in- termediates for the preparation of N-acylated-4-aryl- amino acid derivatives: WO, 2010078440 E P ]. 2010 - 08 - 07.
  • 5LIU F, YU W S, OU W H, et al. The synthesis of a chiral-amino acid derivative by the Grignard reaction of an aspartic acid equivalent [ J ]. J Chem Res, 2010,34(9) :517 -519.
  • 6朱国良,张健,杨立军,等.西他列汀及其制备方法和用途:WO,2011035725[P].2011-03-31.
  • 7KIM D,WANG L P, BECONI M. (2R)-4-Oxo-4- E 3- ( trifluoromethyl ) -5,6-dihydro m 1,2,4 ] triazolo E 4,3-a pyrazin-7 (8H) -yl ] -1- ( 2,4,5-trifluorophe- nyl) butan-2-amine : a potent, orally active dipeptidy peptidase IV inhibitor for the treatment of type 2 dia- betes[ J]. J Med Chem,2005,48( 11 ) :141 -151.
  • 8KIM D, KOWALCHICK J E, EDMONDSON S D. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JanuviaTM ( sitagliptin phosphate) [ J]. Bioorg Med Chem Lettl 2007, 17 (12) :3373 -3377.
  • 9CIMARELLI C, PALMIERI G. Stereoselective re- duction of enantiopure/3-enamino esters by hydride : a convenient synthesis of both enantiopure fl-amino es- ters [ J ]. J Org Chem, 1996,61 ( 16 ) : 5557 - 5563.
  • 10KUBIYK M,HANSEN K B. Application of the asyrnmetric hydrogenation of enamines to the prepa- ration of a beta-amino acid pharmacophpre [ J ]. Tet- rahedron: Asymmetry ,2006,17 (2) : 205 - 209.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部